{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:46:47Z","timestamp":1794008807502,"version":"4.8.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"crossref","award":["1R01GM114128"],"award-info":[{"award-number":["1R01GM114128"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"crossref","award":["UL1TR000427"],"award-info":[{"award-number":["UL1TR000427"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"crossref","award":["1R01GM114128"],"award-info":[{"award-number":["1R01GM114128"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"crossref","award":["UL1TR000427"],"award-info":[{"award-number":["UL1TR000427"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,4]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n \n A significant knowledge gap exists in\n SLC5A2<\/jats:italic>\n 's role in familial renal glycosuria and sodium-glucose cotransporter-2 inhibitors' efficacy.\n <\/jats:p>\n <\/jats:list-item>\n \n \n Two percent of individuals in the All-of-Us cohort harbor rare genetic variants in\n SLC5A2<\/jats:italic>\n , potentially increasing the risk of familial renal glycosuria.\n <\/jats:p>\n <\/jats:list-item>\n \n \n Our trial suggests differential responses to sodium-glucose cotransporter-2 inhibitors in individuals with rare\n SLC5A2<\/jats:italic>\n alleles compared with wild types.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Renal glucosuria is a rare inheritable trait caused by loss-of-function variants in the gene that encodes sodium-glucose cotransporter-2 (SGLT2) (\n i.e<\/jats:italic>\n .,\n SLC5A2<\/jats:italic>\n ). The genetics of renal glucosuria is poorly understood, and even less is known on how loss-of-function variants in\n SLC5A2<\/jats:italic>\n may affect response to SGLT2 inhibitors, a new class of medication gaining popularity to treat diabetes by artificially inducing glucosuria.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We used two biobanks that link genomic with electronic health record data to study the genetics of renal glucosuria. This included 245,394 participants enrolled in the All of Us Research Program and 11,011 enrolled in Marshfield Clinic's Personalized Research Project (PMRP). Association studies in All of Us and PMRP identified ten variants that reached an experiment-wise Bonferroni threshold in either cohort, of which nine were novel. PMRP was further used as a recruitment source for a prospective SGLT2 pharmacogenetic trial. During a glucose tolerance test, the trial measured urine glucose concentrations in 15\n SLC5A2<\/jats:italic>\n variant\u2013positive individuals and 15 matched wild types with and without an SGLT2 inhibitor.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n This trial demonstrated that carriers of\n SLC5A2<\/jats:italic>\n risk variants may be more sensitive to SGLT2 inhibitors compared with wild types (\n P<\/jats:italic>\n = 0.075). On the basis of population data, 2% of an ethnically diverse population carried rare variants in\n SLC5A2<\/jats:italic>\n and are at risk of renal glucosuria.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n As a result, 2% of individuals being treated with SGLT2 inhibitors may respond differently to this new class of medication compared with the general population, suggesting that a larger investigation into\n SLC5A2<\/jats:italic>\n variants and SGLT2 inhibitors is needed.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000000621","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:06:34Z","timestamp":1729080394000},"page":"521-530","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Familial Renal Glucosuria and Potential Pharmacogenetic Impact on Sodium-Glucose Cotransporter-2 Inhibitors"],"prefix":"10.34067","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-4235","authenticated-orcid":false,"given":"Patrick","family":"Allaire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-2361","authenticated-orcid":false,"given":"Jamie","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrie","family":"Kitchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-5689","authenticated-orcid":false,"given":"Rachel","family":"Gabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Folz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Bettadahalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hebbring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"issue":"1","key":"B1-20250609","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health."},{"issue":"3","key":"B2-20250609","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs."},{"issue":"7892","key":"B3-20250609","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-021-04211-w","article-title":"Structure and mechanism of the SGLT family of glucose transporters","volume":"601","author":"Han","year":"2022","journal-title":"Nature."},{"issue":"2","key":"B4-20250609","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"B6-20250609","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs."},{"issue":"suppl 1","key":"B7-20250609","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.amjcard.2019.10.029","article-title":"Safety of sodium-glucose Co-transporter 2 inhibitors","volume":"124","author":"McGill","year":"2019","journal-title":"Am J Cardiol."},{"issue":"10","key":"B8-20250609","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/0026-0495(71)90017-5","article-title":"Autosomal recessive inheritance of renal glycosuria","volume":"20","author":"Elsas","year":"1971","journal-title":"Metabolism."},{"issue":"3","key":"B9-20250609","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00439-003-1054-x","article-title":"Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria","volume":"114","author":"Calado","year":"2004","journal-title":"Hum Genet."},{"issue":"3","key":"B11-20250609","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00439-010-0927-z","article-title":"Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients","volume":"129","author":"Yu","year":"2011","journal-title":"Hum Genet."},{"issue":"7","key":"B12-20250609","first-page":"301","article-title":"Renal glycosuria: dominant or recessive autosome anomaly? Mode of hereditary transmission based on the analysis of a 3-generation family tree","volume":"74","author":"De Marchi","year":"1983","journal-title":"Minerva Med."},{"issue":"7","key":"B13-20250609","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201call of us\u201d research program","volume":"381","author":"Denny","year":"2019","journal-title":"N Engl J Med."},{"issue":"3","key":"B14-20250609","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jamia\/ocu023","article-title":"Feasibility and utility of applications of the common data model to multiple, disparate observational health databases","volume":"22","author":"Voss","year":"2015","journal-title":"J Am Med Inform Assoc."},{"issue":"16","key":"B15-20250609","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/bioinformatics\/btu197","article-title":"R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment","volume":"30","author":"Carroll","year":"2014","journal-title":"Bioinformatics."},{"issue":"7","key":"B16-20250609","doi-asserted-by":"crossref","first-page":"e0175508","DOI":"10.1371\/journal.pone.0175508","article-title":"Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record","volume":"12","author":"Wei","year":"2017","journal-title":"PLoS One."},{"issue":"4","key":"B17-20250609","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/ejhg.2014.123","article-title":"Phenome-wide association studies (PheWASs) for functional variants","volume":"23","author":"Ye","year":"2015","journal-title":"Eur J Hum Genet."},{"issue":"10","key":"B18-20250609","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jmedgenet-2016-103867","article-title":"Phenome-wide association study maps new diseases to the human major histocompatibility complex region","volume":"53","author":"Liu","year":"2016","journal-title":"J Med Genet."},{"issue":"3","key":"B19-20250609","first-page":"100201","article-title":"Genetic and clinical determinants of telomere length","volume":"4","author":"Allaire","year":"2023","journal-title":"HGG Adv."},{"issue":"2","key":"B20-20250609","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet."},{"key":"B21-20250609","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.genom.9.081307.164258","article-title":"African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping","volume":"9","author":"Campbell","year":"2008","journal-title":"Annu Rev Genomics Hum Genet."},{"issue":"9","key":"B22-20250609","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41588-023-01465-0","article-title":"Genome-wide prediction of disease variant effects with a deep protein language model","volume":"55","author":"Brandes","year":"2023","journal-title":"Nat Genet."},{"issue":"4","key":"B23-20250609","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens."},{"issue":"15","key":"B24-20250609","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"11","key":"B25-20250609","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"21","key":"B26-20250609","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"issue":"7","key":"B27-20250609","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"B29-20250609","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00264-019-04433-8","article-title":"Is there scientific evidence to support antibiotic prophylaxis in patients with periodontal disease as a means to decrease the risk of prosthetic joint infections? A systematic review","volume":"44","author":"Moreira","year":"2020","journal-title":"Int Orthop."},{"issue":"7892","key":"B31-20250609","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41586-021-04212-9","article-title":"Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter","volume":"601","author":"Niu","year":"2022","journal-title":"Nature."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:59:27Z","timestamp":1786478367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000621","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"2024-01-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}